Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2006 May;98(5):772–778.

Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia.

Roxanne A Rodney 1, Daniel Sugimoto 1, Bernard Wagman 1, Franklin Zieve 1, Boris Kerzner 1, John Strony 1, Bo Yang 1, Ramachandran Suresh 1, Enrico Veltri 1
PMCID: PMC2569293  PMID: 16749654

Abstract

The purpose of this study was to examine the efficacy and safety of ezetimibe (EZE) coadministered with simvastatin (SIMVA) in a large cohort of African Americans with primary hypercholesterolemia. In a multicenter, randomized, double-blind study, patients were considered eligible for enrollment if after a washout/placebo run-in period, low-density-lipoprotein (LDL) cholesterol level was > or = 145 and < or = 250 mg/dl and triglyceride level was < or = 350 mg/dl. Eligible patients were randomized to SIMVA 20 mg coadministered with either EZE 10 mg (n = 124) or placebo (n = 123) for 12 weeks. At study endpoint, EZE/SIMVA 10/20 mg resulted in a significant mean percent reduction in LDL cholesterol from baseline of 45.6% compared with 28.3% for SIMVA 20 mg alone (p < or = 0.01). There were significantly greater mean reductions in total cholesterol (33% vs. 21%), triglycerides (median 22% vs. 15%), nonhigh-density-lipoprotein (non-HDL) cholesterol (42% vs. 26%), and apolipoprotein B (38% vs. 25%) with EZE/SIMVA 10/20 mg compared with SIMVA 20 mg alone, respectively (p < or = 0.01). There was no difference in HDL cholesterol between the EZE/SIMVA 10/20-mg and SIMVA 20-mg alone groups (+1% vs. +2%, respectively). Coadministration of EZE/SIMVA 10/20 mg demonstrated a safety profile similar to that of SIMVA 20 mg. In conclusion, EZE/SIMVA 10/20 mg provided significantly greater improvement in atherogenic lipid profiles and was well tolerated compared with SIMVA 20-mg monotherapy in a large cohort of African Americans with primary hypercholesterolemia.

Full text

PDF
772

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballantyne Christie M., Houri John, Notarbartolo Alberto, Melani Lorenzo, Lipka Leslie J., Suresh Ramachandran, Sun Steven, LeBeaut Alexandre P., Sager Philip T., Veltri Enrico P. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 Apr 28;107(19):2409–2415. doi: 10.1161/01.CIR.0000068312.21969.C8. [DOI] [PubMed] [Google Scholar]
  2. Davidson M. H., Ballantyne C. M., Kerzner B., Melani L., Sager P. T., Lipka L., Strony J., Suresh R., Veltri E., Ezetimibe Study Group Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug;58(8):746–755. doi: 10.1111/j.1368-5031.2004.00289.x. [DOI] [PubMed] [Google Scholar]
  3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486–2497. doi: 10.1001/jama.285.19.2486. [DOI] [PubMed] [Google Scholar]
  4. Feldman Theodore, Koren Michael, Insull William, Jr, McKenney James, Schrott Helmut, Lewin Andrew, Shah Sukrut, Sidisin Michelle, Cho Meehyung, Kush Debra. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004 Jun 15;93(12):1481–1486. doi: 10.1016/j.amjcard.2004.02.059. [DOI] [PubMed] [Google Scholar]
  5. Ferdinand Keith C., Clark Luther T., Watson Karol E., Neal Ryan C., Brown Clinton D., Kong B. Waine, Barnes Boisey O., Cox William R., Zieve Franklin J., Isaacsohn Jonathan. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol. 2005 Nov 28;97(2):229–235. doi: 10.1016/j.amjcard.2005.08.026. [DOI] [PubMed] [Google Scholar]
  6. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499–502. [PubMed] [Google Scholar]
  7. Goldberg Anne C., Sapre Aditi, Liu Ji, Capece Rachel, Mitchel Yale B., Ezetimibe Study Group Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004 May;79(5):620–629. doi: 10.4065/79.5.620. [DOI] [PubMed] [Google Scholar]
  8. Grundy Scott M. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002 Jun 11;105(23):2696–2698. doi: 10.1161/01.cir.0000020650.86137.84. [DOI] [PubMed] [Google Scholar]
  9. Kerzner Boris, Corbelli John, Sharp Stephan, Lipka Leslie J., Melani Lorenzo, LeBeaut Alexandre, Suresh Ramachandran, Mukhopadhyay Pabak, Veltri Enrico P., Ezetimibe Study Group Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol. 2003 Feb 15;91(4):418–424. doi: 10.1016/s0002-9149(02)03236-8. [DOI] [PubMed] [Google Scholar]
  10. Knopp R. H. Drug treatment of lipid disorders. N Engl J Med. 1999 Aug 12;341(7):498–511. doi: 10.1056/NEJM199908123410707. [DOI] [PubMed] [Google Scholar]
  11. Knopp R. H., Dujovne C. A., Le Beaut A., Lipka L. J., Suresh R., Veltri E. P., Ezetimbe Study Group Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003 Jun;57(5):363–368. [PubMed] [Google Scholar]
  12. Melani Lorenzo, Mills Richard, Hassman David, Lipetz Robert, Lipka Leslie, LeBeaut Alexandre, Suresh Ramachandran, Mukhopadhyay Pabak, Veltri Enrico, Ezetimibe Study Group Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J. 2003 Apr;24(8):717–728. doi: 10.1016/s0195-668x(02)00803-5. [DOI] [PubMed] [Google Scholar]
  13. Ockene I. S., Matthews C. E., Rifai N., Ridker P. M., Reed G., Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 2001 Mar;47(3):444–450. [PubMed] [Google Scholar]
  14. Sager Philip T., Capece Rachel, Lipka Leslie, Strony John, Yang Bo, Suresh Ramachandran, Mitchel Yale, Veltri Enrico. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis. 2004 Dec 15;179(2):361–367. doi: 10.1016/j.atherosclerosis.2004.10.021. [DOI] [PubMed] [Google Scholar]
  15. Sager Philip T., Melani Lorenzo, Lipka Leslie, Strony John, Yang Bo, Suresh Ramachandran, Veltri Enrico, Ezetimibe Study Group Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol. 2003 Dec 15;92(12):1414–1418. doi: 10.1016/j.amjcard.2003.08.048. [DOI] [PubMed] [Google Scholar]
  16. Van Heek M., France C. F., Compton D. S., McLeod R. L., Yumibe N. P., Alton K. B., Sybertz E. J., Davis H. R., Jr In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther. 1997 Oct;283(1):157–163. [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES